Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7868301rdf:typepubmed:Citationlld:pubmed
pubmed-article:7868301lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7868301lifeskim:mentionsumls-concept:C0011892lld:lifeskim
pubmed-article:7868301lifeskim:mentionsumls-concept:C0018183lld:lifeskim
pubmed-article:7868301lifeskim:mentionsumls-concept:C0025605lld:lifeskim
pubmed-article:7868301lifeskim:mentionsumls-concept:C0034801lld:lifeskim
pubmed-article:7868301lifeskim:mentionsumls-concept:C0332157lld:lifeskim
pubmed-article:7868301lifeskim:mentionsumls-concept:C0243067lld:lifeskim
pubmed-article:7868301lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:7868301pubmed:issue11lld:pubmed
pubmed-article:7868301pubmed:dateCreated1995-3-28lld:pubmed
pubmed-article:7868301pubmed:abstractTextIn order to elucidate better the immunological effect of opioid abuse in the absence of HIV infection as a confounding factor, granulocyte function was investigated in three groups of HIV-negative subjects, including 20 active parenteral heroin abusers (H), 20 long-term methadone-maintained former opiate abusers (M) and 20 healthy controls (C). Chemotaxis to N-formyl methionyl-leucyl-phenylalanine (fMLP), casein and activated plasma were markedly and similarly reduced (approx. 50%) in both H and M groups, as was true for superoxide production after fMLP and PMA stimulation, 47% decrease of C values. Polymorphonuclear (PMN) of H and M subjects also exhibited a very marked and similar reduction in the expression of CD11b/CD18 integrin receptors after fMLP treatment, with values that were less than 10% of those in controls, as observed by flow cytometry. In parallel, PMN of H and M individuals presented an approximately four-fold increase in opioid receptors numbers compared to controls, a significant inverse correlation existing between the increase in opiate receptors and defective chemotaxis. The possible mechanism underlying the observed changes in PMN of H and M individuals is discussed.lld:pubmed
pubmed-article:7868301pubmed:languageenglld:pubmed
pubmed-article:7868301pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7868301pubmed:citationSubsetIMlld:pubmed
pubmed-article:7868301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7868301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7868301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7868301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7868301pubmed:statusMEDLINElld:pubmed
pubmed-article:7868301pubmed:monthNovlld:pubmed
pubmed-article:7868301pubmed:issn0192-0561lld:pubmed
pubmed-article:7868301pubmed:authorpubmed-author:FossatiGGlld:pubmed
pubmed-article:7868301pubmed:authorpubmed-author:MazzoneAAlld:pubmed
pubmed-article:7868301pubmed:authorpubmed-author:RicevutiGGlld:pubmed
pubmed-article:7868301pubmed:authorpubmed-author:FeaMMlld:pubmed
pubmed-article:7868301pubmed:authorpubmed-author:MazzucchelliI...lld:pubmed
pubmed-article:7868301pubmed:authorpubmed-author:GrittiDDlld:pubmed
pubmed-article:7868301pubmed:issnTypePrintlld:pubmed
pubmed-article:7868301pubmed:volume16lld:pubmed
pubmed-article:7868301pubmed:ownerNLMlld:pubmed
pubmed-article:7868301pubmed:authorsCompleteYlld:pubmed
pubmed-article:7868301pubmed:pagination959-67lld:pubmed
pubmed-article:7868301pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:meshHeadingpubmed-meshheading:7868301-...lld:pubmed
pubmed-article:7868301pubmed:year1994lld:pubmed
pubmed-article:7868301pubmed:articleTitleGranulocyte defects and opioid receptors in chronic exposure to heroin or methadone in humans.lld:pubmed
pubmed-article:7868301pubmed:affiliationDepartment of Internal Medicine and Therapeutics, University of Pavia, IRCCS San Matteo Hospital, Italy.lld:pubmed
pubmed-article:7868301pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7868301pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7868301lld:pubmed